SCHEMBL1923474

SCHEMBL1923474

Cc1ccc2c(=O)c(-c3ccccc3)cn(CC(=O)Nc3nc(C)cs3)c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.47
▸ MAPK1 P28482 4/20 0.46
▸ HSD17B10 Q99714 3/20 0.46
▸ TSHR P16473 2/20 0.46
▸ POLB P06746 2/20 0.46
▸ MAPT P10636 4/20 0.46
▸ SLC12A5 Q9H2X9 2/20 0.46
▸ HPGD P15428 2/20 0.46
▸ ALOX15 P16050 2/20 0.46
▸ SLC12A2 P55011 1/20 0.46
▸ SMN1; SMN2 Q16637 4/20 0.45
▸ HTT P42858 3/20 0.45
▸ NPC1 O15118 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ LMNA P02545 2/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ RXFP1 Q9HBX9 1/20 0.43
▸ USP2 O75604 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ PRNP P04156 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1924395 0.85 RAB9A (0.47) KMT2AHSD17B10POLBMAPTHPGD
SCHEMBL1923590 0.85 USP10 (0.45) KMT2ATSHRPOLBMAPTSMN1; SMN2
SCHEMBL1923509 0.84 USP10 (0.47) POLBMAPTSMN1; SMN2HTTRAB9A
SCHEMBL1923646 0.82 USP10 (0.46) KMT2APOLBMAPTSMN1; SMN2HTT
SCHEMBL1923602 0.82 CPT2 (0.55) KMT2AMAPTSMN1; SMN2HTTLMNA
SCHEMBL1923480 0.81 USP10 (0.44) POLBMAPTSMN1; SMN2HTTRAB9A
SCHEMBL1923836 0.81 MEN1 (0.50) KMT2ASMN1; SMN2HTTNPC1RAB9A
SCHEMBL1923948 0.81 MEN1 (0.49) KMT2AMAPTSMN1; SMN2HTTNPC1
SCHEMBL1923515 0.80 PKM (0.47) KMT2AHSD17B10TSHRPOLBSMN1; SMN2
SCHEMBL1923615 0.80 USP10 (0.45) KMT2APOLBMAPTSMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2064185-B1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS FERRER INT (ES) 2011-06-08 — — EP claimed
US-20100168099-A1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS FERRER INTERNACIONAL, S.A. (ES) 2010-07-01 — — US claimed
CN-101522630-A 1H-quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions FERRER INT (ES) 2009-09-02 — — CN claimed
EP-2064185-A1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS Ferrer Internacional, S.A. (ES) 2009-06-03 — — EP claimed
WO-2008017710-A1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS FERRER INTERNACIONAL S.A. (ES) 2008-02-14 — — WO claimed
EP-1886996-A1 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions FERRER INTERNACIONAL, S.A. (ES) 2008-02-13 — — EP claimed
EP-2064185-B1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS FERRER INT (ES) 2011-06-08 — — EP disclosed
US-20100168099-A1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS FERRER INTERNACIONAL, S.A. (ES) 2010-07-01 — — US disclosed
CN-101522630-A 1H-quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions FERRER INT (ES) 2009-09-02 — — CN disclosed
EP-2064185-A1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS Ferrer Internacional, S.A. (ES) 2009-06-03 — — EP disclosed
WO-2008017710-A1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS FERRER INTERNACIONAL S.A. (ES) 2008-02-14 — — WO disclosed
EP-1886996-A1 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions FERRER INTERNACIONAL, S.A. (ES) 2008-02-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168099-A1 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS GABRA1, GABRA4, GABRA2 KMT2A 646/4885MAPK1 2959/4885HSD17B10 3072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback